Atherosclerosis最新文献_第6页

Corrigendum to “Rising to the challenge of cardio-renal-metabolic disease in the 21st century: Translating evidence into best clinical practice to prevent and manage atherosclerosis” [Atherosclerosis, Vol 396, (September 2024), 118528] 更正："迎接 21 世纪心肾代谢疾病的挑战：将证据转化为预防和控制动脉粥样硬化的最佳临床实践"[《动脉粥样硬化》，第 396 卷，（2024 年 9 月），第 118528 页]。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118610

International Cardiometabolic Working Group, Andrew Krentz , Stephan Jacob , Christian Heiss , Naveed Sattar , Soo Lim , Kamlesh Khunti , Robert H. Eckel

引用次数: 0

Progression of coronary artery calcium density and major adverse cardiovascular events 冠状动脉钙密度的进展与主要不良心血管事件。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118593

Qingchao Meng, Li Zhao, Na Zhao, Yunqiang An, Bin Lu , Yang Gao

{"title":"Progression of coronary artery calcium density and major adverse cardiovascular events","authors":"Qingchao Meng, Li Zhao, Na Zhao, Yunqiang An, Bin Lu , Yang Gao","doi":"10.1016/j.atherosclerosis.2024.118593","DOIUrl":"10.1016/j.atherosclerosis.2024.118593","url":null,"abstract":"<div><h3>Background and aims</h3><div>We aimed to investigate the relationship between coronary artery calcium (CAC) density progression and major adverse cardiovascular events (MACE), and the prognostic value of CAC density progression.</div></div><div><h3>Methods</h3><div>Patients with serial CAC scans were enrolled in this study. CAC density was directly measured in calcified lesions. Change and rate of progression of CAC density were calculated. Cox proportional hazard regression was utilized to estimate hazard ratios (HRs) for time to MACE regarding CAC density. The incremental prognostic value and the reclassification ability of CAC density progression were evaluated using the C-index and continuous net reclassification index (NRI).</div></div><div><h3>Results</h3><div>304 patients (57.86 ± 9.47 years, 69.4 % male) were included. There were 47 MACE over a follow–up period of 76.00 (56.00–95.00) months. After adjustment for risk factors and CAC volume, the change of CAC density was inversely associated with MACE (per 10HU: HR: 0.956, 95 % confidence interval: 0.920–0.992, <em>p</em> = 0.018). Adding the change of CAC density to risk factors and baseline CAC density improved the C-index (0.694 <em>vs.</em> 0.678, <em>p</em> = 0.026). Adding the change of CAC density improved reclassification of MACE compared with risk factors and baseline CAC density [NRI = 0.432 (0.016–0.789)].</div></div><div><h3>Conclusions</h3><div>CAC density progression is inversely associated with MACE. The addition of the change of CAC density improves prognostic value compared to baseline risk factors and CAC density and optimizes risk reclassification.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118593"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual role of lipids in chronic kidney disease: Pathogenic culprits and therapeutic allies 血脂在慢性肾病中的双重作用：致病元凶与治疗盟友。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118615

Elena Giardini , Dean Moore , Denise Sadlier , Catherine Godson , Eoin Brennan

引用次数: 0

Metabolites derived from radical oxidation of PUFA: NEO-PUFAs, promising molecules for health? 由 PUFA 自由基氧化产生的代谢物：NEO-PUFAs，有望促进健康的分子？

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118600

Anna Abramova , Jamie Bride , Camille Oger , Marie Demion , Jean-Marie Galano , Thierry Durand , Jérôme Roy

{"title":"Metabolites derived from radical oxidation of PUFA: NEO-PUFAs, promising molecules for health?","authors":"Anna Abramova , Jamie Bride , Camille Oger , Marie Demion , Jean-Marie Galano , Thierry Durand , Jérôme Roy","doi":"10.1016/j.atherosclerosis.2024.118600","DOIUrl":"10.1016/j.atherosclerosis.2024.118600","url":null,"abstract":"<div><div>Oxidative stress plays a critical role in numerous pathological processes. Under these stress conditions, the free radical-catalyzed lipid peroxidation generates <em>in vivo</em> a large number of key products that are involved in many physiological and pathophysiological processes. Among these products are neuroprostanes, which arise from the peroxidation of docosahexaenoic acid (DHA), and isoprostanes, resulting from arachidonic acid (AA) and eicosapentaenoic acid (EPA) through the same peroxidation process. These non-enzymatic oxygenated metabolites newly appointed NEO-PUFAs have gained recognition as reliable markers of oxidative stress in neurogenerative and cardiovascular diseases. Moreover, some of them display a wide range of biological activities. The ability to detect and measure these metabolites offers precious insights into the mechanisms of oxidative damage and holds potential therapeutic implications for various health conditions, including neurodegenerative diseases. This review focuses on the role of neuroprostanes as biomarkers for oxidative stress and related diseases, highlighting their potential applications in medical research and treatment.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118600"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nucleic acid liquid biopsies in cardiovascular disease: Cell-free DNA liquid biopsies in cardiovascular disease 心血管疾病中的核酸液体活检：心血管疾病中的无细胞 DNA 液体活检。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118583

Tyler Artner, Smriti Sharma, Irene M. Lang

{"title":"Nucleic acid liquid biopsies in cardiovascular disease: Cell-free DNA liquid biopsies in cardiovascular disease","authors":"Tyler Artner, Smriti Sharma, Irene M. Lang","doi":"10.1016/j.atherosclerosis.2024.118583","DOIUrl":"10.1016/j.atherosclerosis.2024.118583","url":null,"abstract":"<div><div>Cardiovascular disease (CVD) is the leading cause of death worldwide, and despite treatment efforts, cardiovascular function cannot always be restored, and progression of disease be prevented. Critical insights are oftentimes based on tissue samples. Current knowledge of tissue pathology typically relies on invasive biopsies or postmortem samples. Liquid biopsies, which assess circulating mediators to deduce the histology and pathology of distant tissues, have been advancing rapidly in cancer research and offer a promising approach to be translated to the understanding and treatment of CVD. The widely understood elevations in cell-free DNA during acute and chronic cardiovascular conditions, associate with disease, severity, and offer prognostic value. The role of neutrophil extracellular traps (NETs) and circulating nucleases in thrombosis provide a solid rationale for liquid biopsies in CVD. cfDNA originates from various tissue types and cellular sources, including mitochondria and nuclei, and can be used to trace cell and tissue type lineage, as well as to gain insight into the activation status of cells. This article discusses the origin, structure, and potential utility of cfDNA, offering a deeper and less invasive approach for the understanding of the complexities of CVD.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118583"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of colchicine use with cardiovascular and limb events in peripheral artery disease: Insights from a retrospective cohort study 外周动脉疾病患者使用秋水仙碱与心血管和肢体事件的关系：一项回顾性队列研究的启示。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118563

Lucas Tramujas , Alleh Nogueira , Nicole Felix , Pedro Gabriel Melo de Barros e Silva , Alexandre Abizaid , Alexandre Biasi Cavalcanti

{"title":"Association of colchicine use with cardiovascular and limb events in peripheral artery disease: Insights from a retrospective cohort study","authors":"Lucas Tramujas , Alleh Nogueira , Nicole Felix , Pedro Gabriel Melo de Barros e Silva , Alexandre Abizaid , Alexandre Biasi Cavalcanti","doi":"10.1016/j.atherosclerosis.2024.118563","DOIUrl":"10.1016/j.atherosclerosis.2024.118563","url":null,"abstract":"<div><h3>Background and aims</h3><div>Colchicine has demonstrated efficacy in treating coronary artery disease, but its efficacy in peripheral artery disease (PAD) remains uncertain. This study aims to address this gap in knowledge.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted using the TriNetX Network, selecting patients with lower limb PAD between January 1, 2011, and January 1, 2024. Colchicine users were matched 1:1 with non-users through propensity score matching, considering demographics, medical conditions, medications, and psychosocial factors. The primary outcome was a composite of major adverse cardiovascular and limb events (MACLE) - including lower limb amputation, revascularization for lower limb ischemia, acute myocardial infarction, ischemic stroke, and all-cause mortality – over a ten-year follow-up.</div></div><div><h3>Results</h3><div>From 53,568 colchicine-treated and 1,499,969 untreated patients with lower limb PAD, 52,350 pairs were successfully matched. Over ten years, colchicine was associated with a significant reduction in MACLE (hazard ratio, [HR] 0.90, 95% CI 0.88–0.92<em>, p</em> < 0.001), any lower limb amputation (HR 0.84, 95% CI 0.75–0.94, <em>p</em> = 0.002), revascularization for lower limb ischemia (HR 0.85, 95% CI 0.82–0.88, <em>p</em> < 0.001), major adverse cardiovascular events (HR 0.93, 95% CI 0.91–0.95, <em>p</em> < 0.001), and all-cause mortality (HR 0.90, 95% CI 0.87–0.92, <em>p</em> < 0.001). It also result in a reduced risk of ischemic stroke (HR 0.95, 95% CI 0.92–0.98, <em>p</em> = 0.001), but not of acute myocardial infarction (HR 0.98, 95% CI 0.95–1.01<em>, p</em> = 0.24).</div></div><div><h3>Conclusions</h3><div>Colchicine significantly reduced major adverse cardiovascular and limb events in patients with lower limb PAD, supporting the need for further investigation.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118563"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Readmission outcomes after acute coronary syndrome among patients with myeloproliferative neoplasms. 骨髓增生性肿瘤患者急性冠状动脉综合征后再入院的结果。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.119046

Orly Leiva, Sophia Zhou, Joan How, Michelle Lee, Gabriela Hobbs

{"title":"Readmission outcomes after acute coronary syndrome among patients with myeloproliferative neoplasms.","authors":"Orly Leiva, Sophia Zhou, Joan How, Michelle Lee, Gabriela Hobbs","doi":"10.1016/j.atherosclerosis.2024.119046","DOIUrl":"https://doi.org/10.1016/j.atherosclerosis.2024.119046","url":null,"abstract":"<p><strong>Background and aims: </strong>Myeloproliferative neoplasms (MPNs) are associated with arterial thrombosis, including acute coronary syndrome (ACS). Prior studies have suggested similar in-hospital mortality among patients with MPN compared to those without. However, post-ACS outcomes have not been thoroughly evaluated.</p><p><strong>Methods: </strong>Patients hospitalized for ACS with and without MPN from January 2014 to December 2020 were identified using the National Readmission Database (NRD). Primary outcome was 90- and 180-day cardiovascular (CV) readmissions. Secondary outcomes were 90- and 180-day arterial thrombosis (AT), heart failure (HF), bleeding, and all-cause readmission and index hospitalization death, bleeding and arterial thrombosis (including ischemic stroke and arterial thromboembolism). Propensity score matching was used to compare outcomes between patients with and without MPN.</p><p><strong>Results: </strong>After PSM, 8667 patients with MPN were matched with 43,335 patients without MPN. MPN was associated with increased risk of 90- (HR 1.22, 95 % CI 1.13-1.32) and 180-day (HR 1.22, 95 % CI 1.12-1.32) readmissions. MPN was also associated with increased risk of 90- and 180-day AT, HF, bleeding, and all-cause readmissions. Among patients with MPN, MF was associated with increased risk of 90- (HR 1.36, 95 % CI 1.24-1.50) and 180- day (HR 1.34, 95 % CI 1.21-1.48) readmissions.</p><p><strong>Conclusions: </strong>MPN was associated with increased risk of 90- and 180-day readmissions among patients hospitalized for ACS. Among patients with MPN, MF was associated with increased risk of 90- and 180-day CV readmissions. Further investigation is needed to improve post-ACS outcomes among patients with MPN.</p>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"401 ","pages":"119046"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of fatty acids in the pathogenesis of ß-cell failure and Type-2 diabetes 脂肪酸在 ß 细胞衰竭和 2 型糖尿病发病机制中的作用。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118623

Cecilia Jiménez-Sánchez, Lucie Oberhauser, Pierre Maechler

{"title":"Role of fatty acids in the pathogenesis of ß-cell failure and Type-2 diabetes","authors":"Cecilia Jiménez-Sánchez, Lucie Oberhauser, Pierre Maechler","doi":"10.1016/j.atherosclerosis.2024.118623","DOIUrl":"10.1016/j.atherosclerosis.2024.118623","url":null,"abstract":"<div><div>Pancreatic ß-cells are glucose sensors in charge of regulated insulin delivery to the organism, achieving glucose homeostasis and overall energy storage. The latter function promotes obesity when nutrient intake chronically exceeds daily expenditure. In case of ß-cell failure, such weight gain may pave the way for the development of Type-2 diabetes. However, the causal link between excessive body fat mass and potential degradation of ß-cells remains largely unknown and debated. Over the last decades, intensive research has been conducted on the role of lipids in the pathogenesis of ß-cells, also referred to as lipotoxicity. Among various lipid species, the usual suspects are essentially the non-esterified fatty acids (NEFA), in particular the saturated ones such as palmitate. This review describes the fundamentals and the latest advances of research on the role of fatty acids in ß-cells. This includes intracellular pathways and receptor-mediated signaling, both participating in regulated glucose-stimulated insulin secretion as well as being implicated in ß-cell dysfunction. The discussion extends to the contribution of high glucose exposure, or glucotoxicity, to ß-cell defects. Combining glucotoxicity and lipotoxicity results in the synergistic and more deleterious glucolipotoxicity effect. In recent years, alternative roles for intracellular lipids have been uncovered, pointing to a protective function in case of nutrient overload. This requires dynamic storage of NEFA as neutral lipid droplets within the ß-cell, along with active glycerolipid/NEFA cycle allowing subsequent recruitment of lipid species supporting glucose-stimulated insulin secretion. Overall, the latest studies have revealed the two faces of the same coin.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118623"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phospholipid-derived lysophospholipids in (patho)physiology 磷脂衍生的溶血磷脂在（病理）生理学中的作用。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118569

Patricia Prabutzki, Jürgen Schiller, Kathrin M. Engel

{"title":"Phospholipid-derived lysophospholipids in (patho)physiology","authors":"Patricia Prabutzki, Jürgen Schiller, Kathrin M. Engel","doi":"10.1016/j.atherosclerosis.2024.118569","DOIUrl":"10.1016/j.atherosclerosis.2024.118569","url":null,"abstract":"<div><div>Phospholipids (PL) are major components of cellular membranes and changes in PL metabolism have been associated with the pathogenesis of numerous diseases. Lysophosphatidylcholine (LPC) in particular, is a comparably abundant component of oxidatively damaged tissues. LPC originates from the cleavage of phosphatidylcholine (PC) by phospholipase A<sub>2</sub> or the reaction of lipids with reactive oxygen species (ROS) such as HOCl. Another explanation of increased LPC concentration is the decreased re-acylation of LPC into PC. While there are also several other lysophospholipids, LPC is the most abundant lysophospholipid in mammals and will therefore be the focus of this review.</div><div>LPC is involved in many physiological processes. It induces the migration of lymphocytes, fostering the production of pro-inflammatory compounds by inducing oxidative stress. LPC also “signals” via G protein-coupled and Toll-like receptors and has been implicated in the development of different diseases. However, LPCs are not purely “bad”: this is reflected by the fact that the concentration and fatty acyl composition of LPC varies under different conditions, in plasma of healthy and diseased individuals, in tissues and different tumors.</div><div>Targeting LPC and lipid metabolism and restoring homeostasis might be a potential therapeutic method for inflammation-related diseases.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118569"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HMGB2 promotes smooth muscle cell proliferation through PPAR-γ/PGC-1α pathway-mediated glucose changes in aortic dissection 在主动脉夹层中，HMGB2 通过 PPAR-γ/PGC-1α 通路介导的葡萄糖变化促进平滑肌细胞增殖。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-10-31 DOI: 10.1016/j.atherosclerosis.2024.119044

Yameng Zheng , Mengge Yao , Shaokun Chen , Jiakang Li , Xiaozhen Wei , Zhihuang Qiu , Liangwan Chen , Li Zhang

{"title":"HMGB2 promotes smooth muscle cell proliferation through PPAR-γ/PGC-1α pathway-mediated glucose changes in aortic dissection","authors":"Yameng Zheng , Mengge Yao , Shaokun Chen , Jiakang Li , Xiaozhen Wei , Zhihuang Qiu , Liangwan Chen , Li Zhang","doi":"10.1016/j.atherosclerosis.2024.119044","DOIUrl":"10.1016/j.atherosclerosis.2024.119044","url":null,"abstract":"<div><h3>Background and aims</h3><div>Aortic dissection (AD) is a fatal condition with a complicated pathogenesis. High mobility group protein B2 (HMGB2) is a member of the high mobility group protein family; HMGB2 is involved in innate immunity and inflammatory diseases, but its role in AD remains unclear.</div></div><div><h3>Methods</h3><div><em>HMGB2</em><sup><em>−/−</em></sup> mice were generated and treated with β-aminopropionitrile and angiotensin II (Ang II) to establish an AD model. An F12 gel containing AAV9-HMGB2 was applied to overexpress HMGB2 in mice. Pathological changes in the aorta were assessed by visualizing vascular collagen deposition and elastic fiber fracture via H&E, Masson and EVG staining. HMGB2 expression was measured by Western blotting and immunohistochemistry. MTS, CCK-8 and EdU assays were used to test cell proliferation.</div></div><div><h3>Results</h3><div>HMGB2 expression was increased in samples from AD patients, samples from AD mouse modeland human aortic smooth muscle cells (HASMCs). HMGB2 promoted HASMC proliferation. Immunofluorescence staining and plasma membrane protein isolation revealed that HMGB2 decreased GLUT1 expression and promoted GLUT4 translocation. HMGB2 was also found to inhibit the expression of SIRT1/PGC-1α, but blocking the PPAR-γ pathway attenuated this effect. <em>HMGB2</em><sup><em>−/−</em></sup> significantly reduced the incidence and mortality rates of AD, whereas treatment with AAV9-HMGB2 exacerbated AD.</div></div><div><h3>Conclusions</h3><div>This study suggests that HMGB2 promotes HASMC proliferation and vascular remodeling by regulating glucose metabolism through the PPAR-γ/SIRT1/PGC-1α pathway. HMGB2 knockdown reduces, while HMGB2 overexpression promotes, the occurrence of AD in mice. This study may help elucidate the underlying mechanisms and provide a new preventive target for AD.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"399 ","pages":"Article 119044"},"PeriodicalIF":4.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0